Most of the existing research comes from rodent studies
Scientific Support
[PubMed] [Google Scholar] 67.Babu C.S., Shah P.M., Nitahara J
Anticipated Costs Post-Approval While neither compound has reached market, pricing for similar medications provides context: Semaglutide (Wegovy) Approximately $1,300-$1,500 monthly without insurance Tirzepatide (Zepbound) Approximately $1,000-$1,200 monthly without insurance Cagrilintide and retatrutide would likely fall in similar price ranges, with combination therapy potentially costing $2,000-$3,000 monthly without insurance coverage
What the Preclinical Evidence Suggests Lets be honest
So, on one hand, those presenting to doctors offices with iron deficiency anemia should be asked about supplement use